Objectives/hypothesis:
Minimum clinically important differences (MCIDs) for the 22-item SinoNasal Outcomes Test (SNOT-22) in patients with chronic rhinosinusitis (CRS) electing endoscopic sinus surgery (ESS) are well described. However, similar estimations for the MCID have not been investigated for patients electing continued appropriate medical therapy (CAMT). We sought to determine MCID values for a medically treated CRS cohort and compare them to historical MCIDs associated with ESS.
Study Design:
Prospective observational cohort study.
Methods:
One hundred twenty patients with refractory CRS electing CAMT were prospectively enrolled from academic referral clinics into an observational cohort study. Baseline and posttreatment SNOT-22 survey responses were collected. Four distribution-based methods for calculating MCIDs (e.g., half-standard deviation, Cohen's d, standard error of measurement, and minimum detectable change) were used to identify a range of MCID values for SNOT-22 total and domain scores.
Results:
The average MCID value for SNOT-22 total scores was 8.0, whereas mean MCID values for rhinologic, extranasal rhinologic, ear/facial, psychological, and sleep symptom domain scores were 3.9, 2.5, 3.3, 3.4, and 2.9, respectively, comparable to previously reported values for patients electing ESS. Although change in SNOT-22 total scores following CAMT exceeded the MCID, none of the average SNOT-22 domain score improvements surpassed their respective MCID thresholds.
Conclusions:
MCID values for SNOT-22 total and domain scores in patients electing CAMT are similar to previously published MCID values associated with ESS, indicating that MCID values are independent of treatment modality selection. Therefore, despite evidence of statistical significance, CAMT for CRS may not be associated with clinically discernable improvements in average SNOT-22 domain scores.
Level Of Evidence:
2c Laryngoscope, 129:31-36, 2019.
Citing Articles
Canadian Real-World Study Long-Term Clinical Results Using Dupilumab for Chronic Rhinosinusitis With Polyps.
Kilty S, Lasso A
J Otolaryngol Head Neck Surg. 2024; 53:19160216241278659.
PMID: 39345032
PMC: 11450752.
DOI: 10.1177/19160216241278659.
Management of chronic rhinosinusitis with nasal polyps in the Asia-Pacific region and Russia: Recommendations from an expert working group.
Karpischenko S, Jung Y, Kim D, Spriggs K, Tsang R, Yeh T
Asia Pac Allergy. 2024; 14(2):77-83.
PMID: 38827258
PMC: 11142757.
DOI: 10.5415/apallergy.0000000000000139.
Predictors of Sinonasal Improvement After Highly Effective Modulator Therapy in Adults with Cystic Fibrosis.
Beswick D, Liu C, Overdevest J, Zemke A, Khatiwada A, Gudis D
Laryngoscope. 2024; 134(9):3965-3973.
PMID: 38634358
PMC: 11305934.
DOI: 10.1002/lary.31438.
Patient-Reported Sinonasal Symptoms and Risk of Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Romich E, Banerjee S, Amudala N, Chou S, Li R, Lee H
Arthritis Care Res (Hoboken). 2024; 76(8):1099-1108.
PMID: 38523260
PMC: 11288776.
DOI: 10.1002/acr.25329.
Sino-nasal Outcome Test (SNOT22) score in adult population with no known sino-nasal disease.
Upreti G, Modi A, Vadher P, Chudasama P
Eur Arch Otorhinolaryngol. 2024; 281(8):4241-4254.
PMID: 38520535
DOI: 10.1007/s00405-024-08557-5.
Management of CRSwNP in Latin America: A multidisciplinary consensus from an expert working group.
Maspero J, Anselmo-Lima W, Bedoya D, Jimenez Chobillon M, Ospina J, Roithmann R
World Allergy Organ J. 2024; 17(3):100886.
PMID: 38463018
PMC: 10924205.
DOI: 10.1016/j.waojou.2024.100886.
Management of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in the Pan-Arab Region: Consensus Recommendations from a Multidisciplinary Expert Working Group.
Marglani O, Al Abri R, Al Ahmad M, Alsaleh S, Abuzakouk M, Kamel R
J Asthma Allergy. 2023; 16:1055-1063.
PMID: 37795191
PMC: 10547061.
DOI: 10.2147/JAA.S413610.
Psychometric Validation and Meaningful Change Thresholds of the New Nasal Polyposis Symptom Diary.
Shih V, Slagle A, Ivanescu C, Flore G, Meyers O, Kreindler J
Ann Otol Rhinol Laryngol. 2023; 132(12):1638-1648.
PMID: 37271980
PMC: 10571433.
DOI: 10.1177/00034894231177769.
Establishing the Minimal Clinically Important Difference and Substantial Clinical Benefit for the Pain Visual Analog Scale in a Postoperative Hand Surgery Population.
Randall D, Zhang Y, Li H, Hubbard J, Kazmers N
J Hand Surg Am. 2022; 47(7):645-653.
PMID: 35644742
PMC: 9271584.
DOI: 10.1016/j.jhsa.2022.03.009.
The minimal clinically important difference of the Patient-Reported Outcomes Measurement Information System (PROMIS) physical function and upper extremity computer adaptive tests and QuickDASH in the setting of elbow trauma.
Randall D, Zhang Y, Harris A, Qiu Y, Li H, Stephens A
JSES Int. 2021; 5(6):1132-1138.
PMID: 34766096
PMC: 8568814.
DOI: 10.1016/j.jseint.2021.06.005.
Effect of low salicylate diet on clinical and inflammatory markers in patients with aspirin exacerbated respiratory disease - a randomized crossover trial.
Sowerby L, Patel K, Schmerk C, Rotenberg B, Rocha T, Sommer D
J Otolaryngol Head Neck Surg. 2021; 50(1):27.
PMID: 33892819
PMC: 8063291.
DOI: 10.1186/s40463-021-00502-4.
Effect of short-course glucocorticoid application on patients with chronic rhinosinusitis with nasal polyps.
Xu Z, Luo X, Xu L, Deng J, Gao W, Jiang L
World Allergy Organ J. 2020; 13(6):100131.
PMID: 32566071
PMC: 7300158.
DOI: 10.1016/j.waojou.2020.100131.
Quality-of-life and olfaction changes observed with short-term medical management of chronic rhinosinusitis.
Thomas A, Mace J, Ramakrishnan V, Alt J, Mattos J, Schlosser R
Int Forum Allergy Rhinol. 2020; 10(5):656-664.
PMID: 32017433
PMC: 7220819.
DOI: 10.1002/alr.22532.
Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients.
McCormick J, Cho D, Lampkin B, Richman J, Hathorne H, Rowe S
Int Forum Allergy Rhinol. 2018; 9(3):292-297.
PMID: 30472785
PMC: 6520980.
DOI: 10.1002/alr.22251.
